StreetInsider.com News Articles

JPMorgan Resumes NovoCure Ltd. (NVCR) at Neutral

Mon, 13 Jul 2026 03:15:32 -0400

JPMorgan analyst Jessica Fye resumes coverage on NovoCure Ltd. (NASDAQ: NVCR) with a Neutral rating and a price target of $17.00.

The analyst comments: “We are moving to a Neutral rating and establishing a $17 December 2027 price target for NVCR. We see valuation reflecting a maturing GBM business plus the prospect for two near-term launches, particularly the one ongoing in pancreatic cancer, in addition to one coming up in brain mets in NSCLC that could accelerate the top line and help define the path to profitability. We view uptake for Optune Pax in pancreatic cancer as the most important near-term

JPMorgan Resumes NovoCure Ltd. (NVCR) at Neutral

Mon, 13 Jul 2026 03:15:32 -0400

JPMorgan analyst Jessica Fye resumes coverage on NovoCure Ltd. (NASDAQ: NVCR) with a Neutral rating and a price target of $17.00.

Form 4 NovoCure Ltd For: Jun 30 Filed by: Puri Michal Nath

Wed, 01 Jul 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260701/26721370.html

Form 4 NovoCure Ltd For: Jun 30 Filed by: Puri Michal Nath

Wed, 01 Jul 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260701/26721370.html

Form 4 NovoCure Ltd For: Jun 30 Filed by: Leonard Frank X

Wed, 01 Jul 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260701/26721292.html

Form 4 NovoCure Ltd For: Jun 30 Filed by: Leonard Frank X

Wed, 01 Jul 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260701/26721292.html

Form 4 NovoCure Ltd For: Jun 30 Filed by: Ben Arye Barak

Wed, 01 Jul 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260701/26721263.html

Form 4 NovoCure Ltd For: Jun 30 Filed by: Ben Arye Barak

Wed, 01 Jul 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260701/26721263.html

Form 4 NovoCure Ltd For: Jun 30 Filed by: Danziger Asaf

Wed, 01 Jul 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260701/26721230.html

Form 4 NovoCure Ltd For: Jun 30 Filed by: Danziger Asaf

Wed, 01 Jul 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260701/26721230.html

Novocure to Report Second Quarter 2026 Financial Results

Wed, 01 Jul 2026 07:00:00 -0400

BAAR, Switzerland--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) will report financial results for the second quarter 2026 on July 23, 2026, before the U.S. financial markets open.

Novocure management will host a conference call and webcast at 8:00 a.m. EDT, July 23, to discuss the company’s financial results for the three-month period that ended June 30, 2026.

To access the conference call by phone, use the following conference call registration link and dial-in details will be provided. To access the webcast, use the following webcast registration link.

The slides presented during the webcast and

Novocure to Report Second Quarter 2026 Financial Results

Wed, 01 Jul 2026 07:00:00 -0400

BAAR, Switzerland--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) will report financial results for the second quarter 2026 on July 23, 2026, before the U.S. financial markets open.

Novocure management will host a conference call and webcast at 8:00 a.m. EDT, July 23, to discuss the company’s financial results for the three-month period that ended June 30, 2026.

To access the conference call by phone, use the following conference call registration link and dial-in details will be provided. To access the webcast, use the following webcast registration link.

The slides presented during the webcast and

Novocure to Report Second Quarter 2026 Financial Results

Wed, 01 Jul 2026 07:00:00 -0400

BAAR, Switzerland--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) will report financial results for the second quarter 2026 on July 23, 2026, before the U.S. financial markets open.

Novocure management will host a conference call and webcast at 8:00 a.m. EDT, July 23, to discuss the company’s financial results for the three-month period that ended June 30, 2026.

To access the conference call by phone, use the following conference call registration link and dial-in details will be provided. To access the webcast, use the following webcast registration link.

The slides presented during the webcast and

Novocure to Report Second Quarter 2026 Financial Results

Wed, 01 Jul 2026 07:00:00 -0400

BAAR, Switzerland--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) will report financial results for the second quarter 2026 on July 23, 2026, before the U.S. financial markets open.

Novocure management will host a conference call and webcast at 8:00 a.m. EDT, July 23, to discuss the company’s financial results for the three-month period that ended June 30, 2026.

To access the conference call by phone, use the following conference call registration link and dial-in details will be provided. To access the webcast, use the following webcast registration link.

The slides presented during the webcast and

Novocure's Optune Pax wins CE Mark for pancreatic cancer